University of Leicester
Browse
Tezepelumab mucus plugging BRIGHTLING SEPTEMBER 2023.pdf (542.82 kB)

Tezepelumab and Mucus Plugs in Patients with Moderate-to-Severe Asthma

Download (542.82 kB)
journal contribution
posted on 2023-10-10, 09:24 authored by Lars H Nordenmark, Åsa Hellqvist, Claire Emson, Sarah Diver, Celeste Porsbjerg, Janet M Griffiths, John D Newell, Samuel Peterson, Beata Pawlikowska, Jane R Parnes, Ayman Megally, Gene Colice, Christopher E Brightling

BACKGROUND

Mucus plugs in asthmatic airways are associated with airway obstruction and the activity of inflammatory cytokines, specifically interleukin (IL)-5 and IL-13, and they may provide an opportunity for targeted therapy. This analysis of the CASCADE (Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma) placebo-controlled trial used computed tomography (CT) imaging to assess mucus plugs in patients with moderate-to-severe, uncontrolled asthma who received tezepelumab or placebo.

METHODS

CASCADE was an exploratory, double-blind, placebo-controlled trial examining the anti-inflammatory effect of tezepelumab. Patients (aged 18 to 75 years old) were randomly assigned 1:1 to 210 mg tezepelumab or placebo every 4 weeks subcutaneously for at least 28 weeks. An expert radiologist, blinded to treatment groups and time points, objectively scored 18 lung segments for the presence of mucus plugs in CT scans obtained before and after treatment; greater numbers of mucus plugs resulted in higher mucus plug scores.

RESULTS

Absolute change from baseline (mean [±standard deviation]) in mucus plug score was −1.7±2.6 in patients receiving tezepelumab (n=37) and 0.0±1.4 in patients receiving placebo (n=45). At baseline, mucus plug scores correlated positively with levels of inflammatory biomarkers (blood eosinophils, eosinophil-derived neurotoxin, fractional exhaled nitric oxide, IL-5, and IL-13) and negatively with lung function measures (prebronchodilator forced expiratory volume in 1 second and forced mid-expiratory flow). In tezepelumab recipients, reductions in mucus plug scores were correlated with improvements in lung function and reductions in blood eosinophil count and levels of eosinophil-derived neurotoxin, a biomarker of eosinophilic degranulation.

CONCLUSIONS

Tezepelumab was associated with a reduction in occlusive mucus plugs versus placebo in a randomized controlled trial in patients with moderate-to-severe, uncontrolled asthma. (Funded by AstraZeneca and Amgen Inc.; ClinicalTrials.gov number, NCT03688074.)

History

Author affiliation

National Institute for Health and Care Research, Leicester Biomedical Research Centre, University of Leicester

Version

  • AM (Accepted Manuscript)

Published in

NEJM Evidence

Volume

2

Issue

10

Publisher

Massachusetts Medical Society

issn

2766-5526

Copyright date

2023

Available date

2023-10-10

Language

en

Usage metrics

    University of Leicester Publications

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC